Get the Stockscreener App
9.63
5.02%
0.46
Pre-market:
9.71
0.08
+0.83%
Novavax Inc stock is traded at $9.63, with a volume of 7.03M.
It is up +5.02% in the last 24 hours and up +41.00% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$9.17
Open:
$9.32
24h Volume:
7.03M
Relative Volume:
1.61
Market Cap:
$1.56B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
4.2237
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
+20.22%
1M Performance:
+41.00%
6M Performance:
+28.92%
1Y Performance:
+4.45%
1-Day Range:
$9.25
$10.02
1-Week Range:
$7.98
$10.13
52-Week Range:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.63 | 1.49B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.84 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.65 | 79.20B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
833.16 | 50.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.35 | 47.29B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
337.79 | 37.55B | 4.98B | 69.59M | 525.67M | 0.5197 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途资讯
Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality - marketscreener.com
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
Why Are Novavax (NVAX) Shares Soaring Today - The Globe and Mail
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Novavax Strikes $500M Licensing Deal with Pfizer for Matrix-M Technology - timothysykes.com
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million By Investing.com - Investing.com South Africa
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal - Yahoo Finance
Novavax (NASDAQ:NVAX) Stock Price Up 8%Still a Buy? - MarketBeat
Novavax Licenses Rights to Key Vaccine Component to Pfizer - The Wall Street Journal
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story - simplywall.st
Novavax’s Adjuvant Licensing Strategy Continues With Pfizer Pact - Citeline News & Insights
BTIG Reiterates Buy Rating for NVAX with $19 Price Target | NVAX Stock News - GuruFocus
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million - Investing.com Canada
Novavax Pops on Pfizer Licensing Deal - GuruFocus
Novavax's (NVAX) Buy Rating Reiterated at BTIG Research - MarketBeat
Novavax Stock Pops After Pfizer Licensing Agreement - Schaeffer's Investment Research
Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant - marketscreener.com
Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc - marketscreener.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer - GuruFocus
Novavax rises on licensing deal with Pfizer (NVAX:NASDAQ) - Seeking Alpha
Investor Outlook: Novavax, Inc. (NVAX) Shows Potential 59.66% Upside Despite Challenges - directorstalkinterviews.com
Novavax Announces Entering into a License Agreement with Pfizer - PR Newswire
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Casey Mark J | EVP, Chief Legal Officer |
Dec 11 '25 |
Option Exercise |
0.00 |
41,899 |
0 |
73,972 |
| Draghia-Akli Ruxandra | Section 16 |
Nov 11 '25 |
Option Exercise |
0.00 |
14,257 |
0 |
14,257 |
| MCGLYNN MARGARET G | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,588 |
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
16.87%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):